Esperion Therapeutics ESPR Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $403.14M+21.3% | $332.31M+186% | $116.33M+54.1% | $75.48M-3.8% | ||
| $47.85M+3.5% | $46.24M-46.3% | $86.11M-27.6% | $118.93M+12.2% | ||
| $165.79M+1.7% | $163.07M+14.4% | $142.52M+30.7% | $109.08M-41.0% | ||
| $342.86M+23.4% | $277.91M+2.2% | $271.9M+6.6% | $254.98M-16.4% | ||
| $129.22M+88.4% | $68.6M+58.6% | $43.27M— | —— | ||
| $60.27M+2.5% | $58.82M+138% | -$155.56M+13.3% | -$179.5M+20.8% | ||
| 15%-2.7pp | 17.7%+151pp | -133.7%+104pp | -237.8%+51.2pp | ||
| $84.6M+42.8% | $59.25M+0.5% | $58.98M+3.8% | $56.81M+22.6% | ||
| $3.49M-56.5% | $8.02M+51.6% | $5.29M+99.5% | $2.65M-33.3% | ||
| -$20.84M+59.7% | -$51.75M+75.3% | -$209.25M— | —— | ||
| $1.84M— | $0— | $0— | —— | ||
| —— | -$51.75M+75.3% | -$209.25M+10.4% | -$233.66M+13.2% | ||
| —— | -$0.25+88.2% | -$2.12+39.9% | -$3.53+62.1% | ||
| $60.38M+2.5% | $58.89M+138% | -$155.4M+13.2% | -$179M+20.8% | ||
| 15%-2.7pp | 17.7%+151pp | -133.6%+104pp | -237.2%+51.1pp | ||
| $60.27M+2.5% | $58.82M+138% | -$155.56M+13.3% | -$179.5M+20.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Esperion Therapeutics's revenue?
- Esperion Therapeutics (ESPR) generated $418.2M in revenue over the trailing twelve months, up 61.1% year over year.
- Is Esperion Therapeutics profitable?
- Esperion Therapeutics is not currently profitable: it reported a net loss of $109.7M over the trailing twelve months, a -34.8% net margin.
- What is Esperion Therapeutics's earnings per share?
- Esperion Therapeutics's diluted EPS over the trailing twelve months is $-0.53.
- Where does Esperion Therapeutics's income statement data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
